Early antiretroviral treatment of infants to attain HIV r

EClinicalMedicine 18, 100241 DOI: 10.1016/j.eclinm.2019.100241

Citation Report

#	Article	IF	CITATIONS
1	Quantifying the Dynamics of HIV Decline in Perinatally Infected Neonates on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 209-218.	2.1	5
2	Early antiretroviral treatment of infants to attain HIV remission: Not just a matter of timing. EClinicalMedicine, 2020, 20, 100284.	7.1	3
3	Early Infant Treatment: Still a Long Way to Go to Reach Human Immunodeficiency Virus Remission. Clinical Infectious Diseases, 2021, 72, 394-395.	5.8	3
4	Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV,the, 2021, 8, e149-e157.	4.7	12
5	Neurodevelopment in early treated HIVâ€infected infants participating in a developmental stimulation programme compared with controls. Child: Care, Health and Development, 2021, 47, 154-162.	1.7	2
6	Viral Reservoir in Early-Treated Human Immunodeficiency Virus-Infected Children and Markers for Sustained Viral Suppression. Clinical Infectious Diseases, 2021, 73, e997-e1003.	5.8	11
7	Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption. Viruses, 2021, 13, 335.	3.3	6
9	Normalization of B Cell Subsets but Not T Follicular Helper Phenotypes in Infants With Very Early Antiretroviral Treatment. Frontiers in Pediatrics, 2021, 9, 618191.	1.9	2
10	Virologic Response to Very Early HIV Treatment in Neonates. Journal of Clinical Medicine, 2021, 10, 2074.	2.4	1
11	Early Initiation of Antiretroviral Therapy Following In Utero HIV Infection Is Associated With Low Viral Reservoirs but Other Factors Determine Viral Rebound. Journal of Infectious Diseases, 2021, 224, 1925-1934.	4.0	9
12	Predictors of Cell-Associated Human Immunodeficiency Virus (HIV)-1 DNA Over 1 Year in Very Early Treated Infants. Clinical Infectious Diseases, 2022, 74, 1047-1054.	5.8	8
13	Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations. Current HIV/AIDS Reports, 2021, 18, 475-482.	3.1	3
14	Early antiretroviral therapy initiation effect on metabolic profile in vertically HIV-1-infected children. Journal of Antimicrobial Chemotherapy, 2021, 76, 2993-3001.	3.0	6
15	Low Pretreatment Viral Loads in Infants With HIV in an Era of High-maternal Antiretroviral Therapy Coverage. Pediatric Infectious Disease Journal, 2021, 40, 55-59.	2.0	3
16	Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure. Frontiers in Immunology, 2021, 12, 757400.	4.8	13
17	An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults. PLoS Pathogens, 2021, 17, e1010090.	4.7	12
18	Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV. Journal of Virology, 2022, 96, JVI0153521.	3.4	3
19	Quantification of CD4 Recovery in Early-Treated Infants Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 546-557.	2.1	4

#	Article	IF	CITATIONS
21	Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era. Frontiers in Immunology, 2022, 13, .	4.8	1
22	Changes to the Simian Immunodeficiency Virus (SIV) Reservoir and Enhanced SIV-Specific Responses in a Rhesus Macaque Model of Functional Cure after Serial Rounds of Romidepsin Administrations. Journal of Virology, 0, , .	3.4	1
23	HIV cure strategies: which ones are appropriate for Africa?. Cellular and Molecular Life Sciences, 2022, 79, .	5.4	4
24	Immune correlates of HIV-1 reservoir cell decline in early-treated infants. Cell Reports, 2022, 40, 111126.	6.4	13
25	Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth. Nature Communications, 2022, 13, .	12.8	1
26	Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy. PLoS Pathogens, 2022, 18, e1010751.	4.7	0
27	Viral Response among Early Treated HIV Perinatally Infected Infants: Description of a Cohort in Southern Mozambique. Healthcare (Switzerland), 2022, 10, 2156.	2.0	1
28	Viral load testing among pregnant women living with HIV in Mutare district of Manicaland province, Zimbabwe. AIDS Research and Therapy, 2022, 19, .	1.7	3
29	A simple model for viral decay dynamics and the distribution of infected cell life spans in SHIV-infected infant rhesus macaques. Mathematical Biosciences, 2023, 356, 108958.	1.9	0
30	Slow progression of pediatric HIV associates with early CD8+ T cell PD-1 expression and a stem-like phenotype. JCI Insight, 2023, 8, .	5.0	2
31	Predictors of intact HIV DNA levels among children in Kenya. Aids, 0, Publish Ahead of Print, .	2.2	1
33	HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. Lancet HIV,the, 2024, 11, e20-e30.	4.7	1
34	Super early treatment for HIV acquired in utero. Lancet HIV,the, 2023, , .	4.7	0
35	More than the Infinite Monkey Theorem: NHP Models in the Development of a Pediatric HIV Cure. Current HIV/AIDS Reports, 2024, 21, 11-29.	3.1	0
36	Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission. Current Opinion in HIV and AIDS, 2024, 19, 79-86.	3.8	0
37	Growth Trajectories Over the First Year of Life Among Early-Treated Infants with Human Immunodeficiency Virus and Infants Who are Human Immunodeficiency Virus-Exposed Uninfected. Journal of Pediatrics, 2024, 270, 114018.	1.8	0

CITATION REPORT